Please login to the form below
GVHD
This page shows the latest GVHD news and features for those working in and with pharma, biotech and healthcare.
FDA approves first drug to prevent graft-versus-host disease
The approval is based on data from two trials. In the phase 2 GVHD-1 study, while patients who received Orencia saw a 97% overall survival rate compared to 84% for ... The second trial, a clinical study known as GVHD-2, used real-world data collected by
Latest news
-
FDA to consider BMS’ Orencia for graft versus host disease
In GvHD, transplanted donor T-cells are triggered by antigenic differences between donor and host causing them to attack the recipient’s healthy tissue and organs.
-
Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
applications including immune tolerance, fibrosis and graft-versus-host disease (GvHD).
-
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
Other complications include graft-versus-host (GvHD) disease, which occurs when the transplanted cells recognise the recipient’s cells as foreign and attack them.
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
On the safety front, bluebird bio also said that no events of acute or chronic graft-versus-host disease (GvHD) have been reported following treatment with Lenti-D, and neither had
-
FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
chronic graft-versus-host disease (GVHD) in patients aged 12 years and older. ... GVHD. In this trial, Jakafi-treated patients experienced significantly greater overall response rates (ORR) compared to BAT at week 24.
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
Conventional stem cell transplants cost anywhere between $500, 000 and $1m, while also carrying the risk of having to treat adverse events such as gvhd for example.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
